<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39006431</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>medRxiv : the preprint server for health sciences</Title><ISOAbbreviation>medRxiv</ISOAbbreviation></Journal><ArticleTitle>Complex patterns of multimorbidity associated with severe COVID-19 and Long COVID.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2023.05.23.23290408</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1101/2023.05.23.23290408</ELocationID><Abstract><AbstractText>Early evidence that patients with (multiple) pre-existing diseases are at highest risk for severe COVID-19 has been instrumental in the pandemic to allocate critical care resources and later vaccination schemes. However, systematic studies exploring the breadth of medical diagnoses, including common, but non-fatal diseases are scarce, but may help to understand severe COVID-19 among patients at supposedly low risk. Here, we systematically harmonized &gt;12 million primary care and hospitalisation health records from ~500,000 UK Biobank participants into 1448 collated disease terms to systematically identify diseases predisposing to severe COVID-19 (requiring hospitalisation or death) and its post-acute sequalae, Long COVID. We identified a total of 679 diseases associated with an increased risk for severe COVID-19 (n=672) and/or Long COVID (n=72) that spanned almost all clinical specialties and were strongly enriched in clusters of cardio-respiratory and endocrine-renal diseases. For 57 diseases, we established consistent evidence to predispose to severe COVID-19 based on survival and genetic susceptibility analyses. This included a possible role of symptoms of malaise and fatigue as a so far largely overlooked risk factor for severe COVID-19. We finally observed partially opposing risk estimates at known risk loci for severe COVID-19 for etiologically related diseases, such as post-inflammatory pulmonary fibrosis (e.g., <i>MUC5B, NPNT,</i> and <i>PSMD3)</i> or rheumatoid arthritis (e.g., <i>TYK2),</i> possibly indicating a segregation of disease mechanisms. Our results provide a unique reference that demonstrates how 1) complex co-occurrence of multiple - including non-fatal - conditions predispose to increased COVID-19 severity and 2) how incorporating the whole breadth of medical diagnosis can guide the interpretation of genetic risk loci.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pietzner</LastName><ForeName>Maik</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-3437-9963</Identifier><AffiliationInfo><Affiliation>Computational Medicine, Berlin Institute of Health at Charit&#xe9; - Universitatsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Precision Healthcare University Research Institute, Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MRC Epidemiology Unit, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denaxas</LastName><ForeName>Spiros</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-9612-7791</Identifier><AffiliationInfo><Affiliation>Institute of Health Informatics, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Data Research UK, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>British Heart Foundation Data Science Centre, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Health Research University College London Hospitals Biomedical Research Centre.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yasmeen</LastName><ForeName>Summaira</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Computational Medicine, Berlin Institute of Health at Charit&#xe9; - Universitatsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulmer</LastName><ForeName>Maria A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Institute of Computational Biology, Helmholtz Zentrum M&#xfc;nchen - German Research Center for Environmental Health, Neuherberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakanishi</LastName><ForeName>Tomoko</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-9510-5646</Identifier><AffiliationInfo><Affiliation>Precision Healthcare University Research Institute, Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arnold</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-4666-0923</Identifier><AffiliationInfo><Affiliation>Institute of Computational Biology, Helmholtz Zentrum M&#xfc;nchen - German Research Center for Environmental Health, Neuherberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kastenm&#xfc;ller</LastName><ForeName>Gabi</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-2368-7322</Identifier><AffiliationInfo><Affiliation>Institute of Computational Biology, Helmholtz Zentrum M&#xfc;nchen - German Research Center for Environmental Health, Neuherberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hemingway</LastName><ForeName>Harry</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-2279-0624</Identifier><AffiliationInfo><Affiliation>Institute of Health Informatics, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Data Research UK, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Health Research University College London Hospitals Biomedical Research Centre.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langenberg</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Computational Medicine, Berlin Institute of Health at Charit&#xe9; - Universitatsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Precision Healthcare University Research Institute, Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MRC Epidemiology Unit, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U19 AG074879</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG069901</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG063744</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG059093</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG061359</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG081322</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000076942">Preprint</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>medRxiv</MedlineTA><NlmUniqueID>101767986</NlmUniqueID></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="UpdateIn"><RefSource>Commun Med (Lond). 2024 Jul 8;4(1):94. doi: 10.1038/s43856-024-00506-x</RefSource><PMID Version="1">38977844</PMID></CommentsCorrections></CommentsCorrectionsList><CoiStatement>Declaration of Interest None of the authors have a conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>15</Day><Hour>5</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39006431</ArticleId><ArticleId IdType="pmc">PMC11245059</ArticleId><ArticleId IdType="doi">10.1101/2023.05.23.23290408</ArticleId><ArticleId IdType="pii">2023.05.23.23290408</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Merad M., Blish C. A., Sallusto F. &amp; Iwasaki A. The immunology and immunopathology of COVID-19. Science 375, 1122&#x2013;1127 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35271343</ArticleId></ArticleIdList></Reference><Reference><Citation> GOV.uk.  No Title.  https://www.gov.uk/government/news/clinically-extremely-vulnerable-receive-updated-guidance-in-line-with-new-national-restrictions.</Citation></Reference><Reference><Citation>Kompaniyets L. et al. Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020-March 2021. Prev. Chronic. Dis. 18, E66 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8269743</ArticleId><ArticleId IdType="pubmed">34197283</ArticleId></ArticleIdList></Reference><Reference><Citation>Booth A. et al. Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis. PloS One 16, e0247461 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7932512</ArticleId><ArticleId IdType="pubmed">33661992</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson E. J. et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 584, 430&#x2013;436 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611074</ArticleId><ArticleId IdType="pubmed">32640463</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeigue P. M. et al. Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study. PLoS Med. 17, 1&#x2013;17 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7575101</ArticleId><ArticleId IdType="pubmed">33079969</ArticleId></ArticleIdList></Reference><Reference><Citation>Pairo-Castineira E. et al. GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19. Nature (2023) doi:10.1038/s41586-023-06034-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06034-3</ArticleId><ArticleId IdType="pmc">PMC10208981</ArticleId><ArticleId IdType="pubmed">37198478</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Host Genetics Initiative. A second update on mapping the human genetic architecture of COVID-19. Nature 621, E7&#x2013;E26 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10482689</ArticleId><ArticleId IdType="pubmed">37674002</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W.-Q. et al. Evaluating phecodes, clinical classification software, and ICD-9-CM codes for phenome-wide association studies in the electronic health record. (2017) doi:10.1371/journal.pone.0175508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0175508</ArticleId><ArticleId IdType="pmc">PMC5501393</ArticleId><ArticleId IdType="pubmed">28686612</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastarache L. Using Phecodes for Research with the Electronic Health Record: From PheWAS to PheRS. Annu. Rev. Biomed. Data Sci. 4, 1&#x2013;19 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9307256</ArticleId><ArticleId IdType="pubmed">34465180</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu P. et al. Mapping ICD-10 and ICD-10-CM Codes to Phecodes: Workflow Development and Initial Evaluation. JMIR Med. Inform. 7, e14325 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6911227</ArticleId><ArticleId IdType="pubmed">31553307</ArticleId></ArticleIdList></Reference><Reference><Citation>Su S. et al. Epidemiology, clinical presentation, pathophysiology, and management of long COVID: an update. Mol. Psychiatry (2023) doi:10.1038/s41380-023-02171-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-023-02171-3</ArticleId><ArticleId IdType="pubmed">37491461</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuan V. et al. Identifying and visualising multimorbidity and comorbidity patterns in patients in the English National Health Service: a population-based study. Lancet Digit. Health 5, e16&#x2013;e27 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36460578</ArticleId></ArticleIdList></Reference><Reference><Citation>Lammi V. et al. Genome-wide Association Study of Long COVID Authors. 1&#x2013;25 (2023).</Citation></Reference><Reference><Citation>Pairo-Castineira E. et al. Genetic mechanisms of critical illness in COVID-19. Nature 591, 92&#x2013;98 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33307546</ArticleId></ArticleIdList></Reference><Reference><Citation>Letter T. M. An EUA for baricitinib (Olumiant) for COVID-19. Med. Lett. Drugs Ther. 62, 202&#x2013;203 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33451175</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalil A. C. et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N. Engl. J. Med. 384, 795&#x2013;807 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745180</ArticleId><ArticleId IdType="pubmed">33306283</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoang T. N. et al. Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques. Cell 184, 460&#x2013;475.e21 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7654323</ArticleId><ArticleId IdType="pubmed">33278358</ArticleId></ArticleIdList></Reference><Reference><Citation>Chimalakonda A. et al. Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors. Dermatol. Ther. 11, 1763&#x2013;1776 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8484413</ArticleId><ArticleId IdType="pubmed">34471993</ArticleId></ArticleIdList></Reference><Reference><Citation>Elyoussfi S., Rane S. S., Eyre S. &amp; Warren R. B. TYK2 as a novel therapeutic target in psoriasis. Expert Rev. Clin. Pharmacol. 16, 549&#x2013;558 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37287330</ArticleId></ArticleIdList></Reference><Reference><Citation>Strobl B. et al. Novel functions of tyrosine kinase 2 in the antiviral defense against murine cytomegalovirus. J. Immunol. BalHm. Md 1950 175, 4000&#x2013;8 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16148148</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H. E., McCorkell L., Vogel J. M. &amp; Topol E. J. Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 21, 133&#x2013;146 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma A. et al. A Phenome-Wide Association Study of genes associated with COVID-19 severity reveals shared genetics with complex diseases in the Million Veteran Program. PLoS Genet. 18, e1010113 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9049369</ArticleId><ArticleId IdType="pubmed">35482673</ArticleId></ArticleIdList></Reference><Reference><Citation>Fadista J. et al. Shared genetic etiology between idiopathic pulmonary fibrosis and COVID-19 severity. EBioMedicine 65, 103277 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7946355</ArticleId><ArticleId IdType="pubmed">33714028</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma A. et al. A MUC5B Gene Polymorphism, rs35705950-T, Confers Protective Effects Against COVID-19 Hospitalization but Not Severe Disease or Mortality. Am. J. Respir. Crit. Care Med. 206, 1220&#x2013;1229 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9746845</ArticleId><ArticleId IdType="pubmed">35771531</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudlow C. et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 12, e1001779 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4380465</ArticleId><ArticleId IdType="pubmed">25826379</ArticleId></ArticleIdList></Reference><Reference><Citation>Bycroft C. et al. The UK Biobank resource with deep phenotyping and genomic data. Nature 562, 203&#x2013;209 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6786975</ArticleId><ArticleId IdType="pubmed">30305743</ArticleId></ArticleIdList></Reference><Reference><Citation>Thygesen J. H. et al. COVID-19 trajectories among 57 million adults in England: a cohort study using electronic health records. Lancet Digit. Health 4, e542&#x2013;e557 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9179175</ArticleId><ArticleId IdType="pubmed">35690576</ArticleId></ArticleIdList></Reference><Reference><Citation>Denaxas S. Mapping the Read2/CTV3 controlled clinical terminologies to Phecodes in UK Biobank primary care electronic health records: implementation and evaluation. Proc Am. Med. Inform. Assoc. Annu. Symp. 2021 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8861677</ArticleId><ArticleId IdType="pubmed">35308936</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastarache L. Using Phecodes for Research with the Electronic Health Record: From PheWAS to PheRS. Annu. Rev. Biomed. Data Sci. 4, 1&#x2013;19 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9307256</ArticleId><ArticleId IdType="pubmed">34465180</ArticleId></ArticleIdList></Reference><Reference><Citation>Zang C. et al. Data-driven analysis to understand long COVID using electronic health records from the RECOVER initiative. Nat. Commun. 14, 1948 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10080528</ArticleId><ArticleId IdType="pubmed">37029117</ArticleId></ArticleIdList></Reference><Reference><Citation>Barabasi A. &amp; Albert R. Emergence of scaling in random networks. Science 286, 509&#x2013;12 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10521342</ArticleId></ArticleIdList></Reference><Reference><Citation>Mbatchou J. et al. Computationally efficient whole-genome regression for quantitative and binary traits. Nat. Genet. 53, 1097&#x2013;1103 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34017140</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulik-Sullivan B. K. et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat. Genet. 47, 291&#x2013;5 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4495769</ArticleId><ArticleId IdType="pubmed">25642630</ArticleId></ArticleIdList></Reference><Reference><Citation>Verbanck M., Chen C.-Y., Neale B. &amp; Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat. Genet. 50, 693&#x2013;698 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6083837</ArticleId><ArticleId IdType="pubmed">29686387</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-19. Nature 600, 472&#x2013;477 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8674144</ArticleId><ArticleId IdType="pubmed">34237774</ArticleId></ArticleIdList></Reference><Reference><Citation>Yavorska O. O. &amp; Burgess S. Mendelian Randomization: an R package for performing Mendelian randomization analyses using summarized data. Int. J. Epidemiol. 46, 1734&#x2013;1739 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5510723</ArticleId><ArticleId IdType="pubmed">28398548</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemani G. et al. The MR-Base platform supports systematic causal inference across the human phenome. eLife 7, (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5976434</ArticleId><ArticleId IdType="pubmed">29846171</ArticleId></ArticleIdList></Reference><Reference><Citation>Giambartolomei C. et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet. 10, e1004383 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4022491</ArticleId><ArticleId IdType="pubmed">24830394</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace C. A more accurate method for colocalisation analysis allowing for multiple causal variants. PLoS Genet. 17, e1009440 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8504726</ArticleId><ArticleId IdType="pubmed">34587156</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>